详情页

当前位置：首页 > 详情页

Nonmetastatic cell 1 gene polymorphisms are associated with the clinical progression and prognoses of patients with colorectal cancer

1| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of General Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. [2]Department of Gastrointestinal Surgery, Affiliated Hospital of Hebei University, Baoding, Hebei, China. [3]Department of General Surgery, Peoples Hospital of Linxi County, Xingtai, Hebei, China. [4]Department of General Surgery, Zhangjiakou First Hospital, Zhangjiakou, Hebei, China. [5]Department of Endocrinology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

出处：

DOI：

ISSN：

关键词： NME1 polymorphism colorectal cancer risk prognosis

摘要：

Genetic polymorphisms in the nonmetastatic cell 1 gene (NME1) are reportedly associated with the risk of various tumors and the prognoses of cancer patients. The aims of this study were to evaluate the contribution of two polymorphisms of NME1 to the risk of colorectal cancer (CRC) development and the clinical outcomes of CRC patients in a northern Chinese population.This study included 453 CRC patients and 464 controls. Genotyping of two polymorphisms (rs2302254 and rs16949649) in the promoter region of NME1 was performed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.The results revealed that the rs2302254 and rs16949649 polymorphisms were not associated with the risk of CRC. However, the rs2302254 TT mutant genotype was associated with an increased risk for advanced clinical stage and lymph node metastasis. Moreover, survival analysis revealed that patients with the homozygous mutant TT genotype of rs2302254 had significantly shorter disease-free survival (DFS) and overall survival (OS) times than patients with the homozygous wild-type CC genotype.The rs2302254 polymorphism might function as a potential molecular marker for predicting the progression and prognosis of CRC.Copyright © 2025 Liu, Bai, Zhang, Xu and Kong.

基金：

语种：

WOS：

PubmedID：

中科院分区：

出版当年[2025]版：

大类 | 3 区生物学

小类 | 3 区遗传学

最新[2025]版：

大类 | 3 区生物学

小类 | 3 区遗传学

JCR分区：

出版当年[2024]版：

Q2 GENETICS & HEREDITY

最新[2024]版：

Q2 GENETICS & HEREDITY

影响因子： 2.8 最新[2024版] 3.3 最新五年平均 2.8 出版当年[2025版] 3.3 出版当年五年平均 2.8 出版前一年[2024版]

第一作者：

第一作者机构： [1]Department of General Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

通讯作者：

通讯机构： [5]Department of Endocrinology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The TIM-3 Rs10053538 Polymorphism Is Associated with Clinical Prognosis of Colorectal Cancer [2]The TIM-3 Rs10053538 Polymorphism Is Associated with Clinical Prognosis of Colorectal Cancer [3]A Functional Polymorphism in the Promoter Region of Interleukin-12B Increases the Risk of Colorectal Cancer [4]Association between different types of preoperative anemia and tumor characteristics, systemic inflammation, and survival in colorectal cancer [5]华北地区结直肠癌发病风险与基质金属蛋白酶-9表达及基因多态性的相关性 [6]A functional polymorphism rs11614913 in microRNA-196a2 is associated with an increased risk of colorectal cancer although not with tumor stage and grade. [7]Genetic polymorphisms of N-acetyltransferase 2 and colorectal cancer risk [8]大肠癌发病风险与细胞间黏附分子-1基因多态性的关系 [9]Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis [10]Hsa_circ_0002320: a novel clinical biomarker for colorectal cancer prognosis